Metabolic Profile and Anthropometric Changes in Schizophrenia

Central Institute of Psychiatry, Ranchi, India2,006 enrolled

Overview

"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "

we aimed to study the effects of antipsychotics, olanzapine, risperidone and haloperidol on development of metabolic syndrome in a drug naïve population suffering from first episode schizophrenia and compared it with a matched healthy control group. We also aimed to examine the prevalence of metabolic syndrome as defined by the two most widely accepted definitions, the ATP IIIA and the IDF.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SCREENING

Masking

DOUBLE

Enrollment

2,006

Conditions

Metabolic Syndrome Diabetes Obesity

Interventions

OlanzapineDRUG

Olanzapine in dose range of 10-20mg

RisperidoneDRUG

Risperidone 1-6mg

HaloperidolDRUG

Haloperidol 10-20mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 40 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age between 18-40 years * Diagnosis of schizophrenia * Drug naive on admission Exclusion Criteria: * Other psychiatric co-morbidity * History of severe physical illness * Alcohol and substance abuse or dependence * History of pre-existing diabetes or hypertension * Family history of hypertension or diabetes

Locations (1)

Central Institute of Psychiatry

Ranchi, India

Outcomes

Primary Outcomes

Study of metabolic profile

Time frame: 6 weeks

Secondary Outcomes

Study of obesity and diabetes

Time frame: 6 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.